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Novel Oral Anticoagulants
New Challenges for Anesthesiologists in Bleeding Patients
I N recent years, tremendous ef-forts have been made to de-
velop new oral anticoagulants for
the prevention of venous throm-
boembolism after surgery and in
medically ill patients, prevention
of stroke in atrial fibrillation, re-
duction of cardiovascular events in
patients with acute coronary syn-
drome, and treatment of con-
firmed acute pulmonary embo-
lism and deep venous thrombosis.
The most prominent modes of ac-
tion by these novel drugs are direct
factor Xa inhibition (rivaroxaban
and apixaban) or thrombin inhibi-
tion (dabigatran). These drugs are
administered orally at fixed doses,
and no monitoring is necessary
compared with prothrombin time
(PT)/international normalized ratio
measurement in patients treated
with oral vitamin K antagonists.1
Dabigatran received approval
by the Food and Drug Administra-
tion (for the prevention of stroke in
patients with atrial fibrillation) as of
October 1, 20102 and rivaroxaban
(for the prevention of venous
thromboembolism after hip and knee arthroplasty3–6) as of
July 1, 2011.
As is the case with all anticoagulants, including (low–
molecular-weight) heparins and vitamin K antagonists, the
new substances have an inherent bleeding risk.1 When these
novel anticoagulants are used for thromboprophylaxis after
hip or knee arthroplasty (and thus for 2–6 weeks at low
dose), the risk of major bleeding in such patients is low.
However, new indications for these novel anticoagulants
may arise with higher doses and longer treatment durations.
Thus, anesthesiologists are likely to increasingly face patients
who have experienced trauma or other causes of bleeding and
who are being treated with these new anticoagulants. The
most pertinent questions for
which we do not yet have com-
plete answers are: How can we
measure the effect on blood coag-
ulation? and How can we specifi-
cally treat such patients?
The study by Godier et al. in
this issue of ANESTHESIOLOGY7 is
very important because it is the
first that addresses these questions
for rivaroxaban, which is now
marketed in more than 100 coun-
tries. This study in rabbits was
designed and executed elegantly:
first, a dose-finding study was per-
formed to find the necessary dose
of intravenous rivaroxaban that
would result in increased bleeding
after a standardized liver and
spleen incision. Consequently, the
lowest rivaroxaban dose (5 mg/kg)
was used in the main experiment,
in which this dose was given in
conjunction with saline, acti-
vated recombinant factor VII
(rFVIIa, 150 g/kg) or pro-
thrombin complex concentrate
(PCC, 40 units/kg), and the ef-
fects on traditional coagulation
tests (PT and activated partial thromboplastin time), bleed-
ing time, rotational thrombelastography, thrombin genera-
tion, and bleeding caused by a standardized liver and spleen
incision were assessed. The attempt to measure “clinical”
bleeding in this setting is a true and important novelty be-
cause previous studies were limited to in vitro coagulation
assays and bleeding time. The three main findings of the
study by Godier et al.7 were (1) with the exception of the
maximum clot firmness in rotational thrombelastography,
all coagulation tests became clearly pathologic and bleeding
caused by the standardized liver and spleen incision increased
in rivaroxaban-treated rabbits compared with control ani-
mals; (2) the addition of rFVIIa and PCC partially normal-
ized most coagulation test results; and (3) neither rFVIIa norPhotograph: J. P. Rathmell.
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“… anesthesiologists are
likely to increasingly face
patients who have experi-
enced trauma or other
causes of bleeding and who
are being treated with these
new anticoagulants.”
 This Editorial View accompanies the following article: Godier
A, Miclot A, Le Bonniec B, Durand M, Fischer A-M, Emmerich
J, Marchand-Leroux C, Lecompte T, Samama C-M: Evalua-
tion of prothrombin complex concentrate and recombinant
activated factor VII to reverse rivaroxaban in a rabbit model.
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PCC reduced bleeding caused by the standardized liver and
spleen incision in rabbits treated with high-dose rivaroxaban.
Rivaroxaban has a distinct effect on the results of most
clinically used coagulation tests, including a significant pro-
longation of PT and activated thromboplastin time and thus
a reduction of (functional) single-factor measurements per-
formed in one of these test systems. Notably, these changes
were measured after administration of only 10 mg rivaroxa-
ban.8 In contrast, thrombin time, fibrinogen, factor XIII,
andD-Dimers are not affected.8 Themagnitude of this effect
depends on the dose and time since the last rivaroxaban
ingestion.9 In addition, thromboelastometry parameters are
dose-dependently affected by rivaroxaban.10 The alterations
in coagulation test results found by Godier et al.7 are similar.
However, all these changes are not specific for rivaroxaban
and thus are of limited value in the treatment of patients with
acute bleeding. In contrast, in the absence of (low–molecu-
lar-weight) heparin, measuring anti-Xa activity might aid
clinicians in deciding whether or not there is a rivaroxaban
effect. Very low anti-Xa activity (e.g.,0.1 U/ml when using
standard anti-Xa assays) suggests that there is no relevant
rivaroxaban effect, whereas greater values suggest such an
effect without directly quantifying it.
When evaluating the findings in the study of Godier
et al.,7 we need to keep in mind that the dose used in this
animal model would be considered a massive overdose of ri-
varoxaban in the clinical setting. The authors first established
the minimum dose of rivaroxaban necessary to induce a clin-
ical coagulopathy with increased bleeding caused by a stan-
dardized liver and spleen incision. The dose established and
used for additional experiments was 5 mg/kg, which is 8–10
times greater than the highest daily dose used in any of the
clinical (human) phase 3 trials. In contrast, the doses of
rFVIIa and PCC were fixed, and both were in the high-
normal range of clinically used doses. Therefore the ineffi-
cacy of both treatments in reducing the bleeding associated
with a standardized liver and spleen incision may reflect a
relative under-dosing of rFVIIa in PCC in this study.
The findings on reversing the anticoagulant effect of ri-
varoxaban in the study of Godier et al.7 are largely in keeping
with the results of previous studies. Perzborn et al. showed
that rFVIIa partially restored thrombin generation in human
platelet-rich plasma because higher doses of rivaroxaban were
necessary for the same amount of thrombin inhibition if
rFVIIa was present (as presented at the 21st Congress of the
International Society on Thrombosis and Hemostasis, Ox-
ford, United Kingdom, August 2007). In rats treated with 2
mg/kg rivaroxaban, Tinel et al. found that a supratherapeutic
dose of rFVIIa (400 g/kg) partially normalized PT and
thrombin generation (as presented at the 21st Congress of
the International Society on Thrombosis and Hemostasis,
Oxford, United Kingdom, August 2007). Finally, in ba-
boons given 0.9 mg/kg rivaroxaban, Gruber et al.11 found
that 210 g/kg rFVIIa shortened bleeding time and PT by
approximately 30%. Thus, we may speculate that rFVIIa
may help to mitigate bleeding in patients treated with rivar-
oxaban outside the context of rivaroxaban overdose. The
following seem reasonable hypotheses: the use of rFVIIa in-
duces direct activation of FX to FXa, where the amount of
FXa generated seems linear to the amount of rFVIIa12; thus,
in the presence of a given amount of a FXa inhibitor, the
balance is shifted toward more available FXa and thus more
thrombin generation, leading to increased soluble fibrin gen-
eration and increased cross-linking of fibrin monomers. In
addition, an enhanced thrombin generation through the use
of rFVIIa may increase platelet adhesion even in the presence
of platelet defects.13 However, it must be recognized that
these hypotheses have been generated from in vitro models.
Similarly, high-dose PCC (50 U/kg) partially normalized
bleeding time and PT in rats treated with rivaroxaban (2
mg/kg), whereas low-dose PCC (25 U/kg) was ineffec-
tive.14 PCC is known to increase prothrombin conversion
in addition to increasing factor concentrations through
supplementation,15 although the exact mechanism behind
this observation remains to be elucidated. The most impor-
tant possibilities are replenishment of relatively deficient co-
agulation factors in an environment of an activated coagula-
tion system and additional coagulation activation through
already activated coagulation factors possibly present in the
concentrate. In a study in volunteers given 20 mg rivaroxa-
ban twice daily for 2.5 days, PCC (50 U/kg) immediately
and completely normalized PT and the endogenous throm-
bin potential.16 This observation in humans is particularly
important because the reversal potential of PCCwas assessed
in the high clinical dosing range of rivaroxaban. However,
only the effect on PT and the endogenous thrombin poten-
tial were studied, not the direct effect on bleeding.
In conclusion, the study by Godier et al.7 is important
because it allows hypothesizing that procoagulants such as
PCC and rFVIIa may help to correct the coagulopathy in
patients treated with factor Xa antagonists. However, the
study was performed in the context of overdosing: the ad-
ministration of procoagulants partially corrected coagulation
test results but did not reduce bleeding caused by the stan-
dardized liver and spleen incision in an animal model. Thus,
additional studies similar to the one by Godier et al.7 using
rivaroxaban doses close to the ones used in the clinical setting
are necessary to guide clinicians on how to specifically treat
patients who have received novel anticoagulants.
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